Reducing Financial Burden, Increasing Access to Oncology Treatments With Growing Shift to Biosimilars
Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the growing shift to biosimilars in oncology and the impact of increased access and reduced financial burden for patients on medication adherence.
Pharmacy Times interviewed Shannon Hough, director of ClinReview in Clinical Content for McKesson, on the growing shift to biosimilars in oncology, which is impacting patients and practices by reducing the financial burden of oncology treatments and increasing access to therapies resulting in greater medication adherence.
During the interview, Hough addresses the impact of increased access and reduced financial burden for patients on medication adherence to oncology treatments, how significant the financial advantages of using biosimilars can be for patients, and what the financial advantages of using biosimilars for pharmacies are.
